Related Experiment Video
Updated: May 14, 2026
Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021
Experience with degarelix in the treatment of prostate cancer
1Atlantic Urology Clinics, 823 82nd Parkway, Myrtle Beach, SC 29572, USA.
Abstract:
Degarelix is a gonadotrophin-releasing hormone (GnRH) antagonist for the first-line treatment of androgen-dependent advanced prostate cancer. It has a direct mechanism of action that blocks the action of GnRH on the pituitary with no initial surge in gonadotrophin or testosterone levels. Degarelix is the most extensively studied and widely available GnRH antagonist worldwide. Clinical studies have demonstrated similar efficacy to the GnRH agonist leuprolide in achieving testosterone suppression in patients with prostate cancer. However, degarelix produces a faster suppression of testosterone and prostate-specific antigen (PSA), with no testosterone surge or microsurges, thus preventing the risk of clinical flare in advanced disease. Clinical trials have demonstrated that degarelix can offer improved disease control when compared with a GnRH agonist in terms of superior PSA progression-free survival (suggesting that degarelix likely delays progression to castration-resistant disease), and a more significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone. Degarelix is generally well tolerated, with no reports of systemic allergic reactions in any clinical studies. In conclusion, degarelix offers clinicians a rational first-line hormonal monotherapy option for the management of advanced prostate cancer.
Insights
Degarelix, a gonadotrophin-releasing hormone (GnRH) antagonist, offers effective first-line treatment for advanced prostate cancer by rapidly suppressing testosterone without a surge. It demonstrates improved disease control and is well-tolerated.
Area of Science:
- Oncology
- Endocrinology
Background:
- Advanced prostate cancer requires effective androgen deprivation therapy.
- Gonadotrophin-releasing hormone (GnRH) antagonists offer a direct mechanism for suppressing testosterone production.
Purpose of the Study:
- To evaluate degarelix as a first-line treatment for androgen-dependent advanced prostate cancer.
- To compare the efficacy and safety of degarelix with GnRH agonists.
Main Methods:
- Clinical studies involving patients with advanced prostate cancer receiving degarelix.
- Comparison of testosterone and prostate-specific antigen (PSA) suppression kinetics.
- Assessment of disease progression and safety profiles.
Main Results:
- Degarelix achieved rapid testosterone and PSA suppression without a testosterone surge or microsurge.
- Degarelix demonstrated comparable efficacy to leuprolide in testosterone suppression.
- Improved PSA progression-free survival and significant impact on bone serum alkaline phosphatase and follicle-stimulating hormone were observed with degarelix compared to GnRH agonists.
- Degarelix was generally well-tolerated with no reported systemic allergic reactions.
Conclusions:
- Degarelix is a safe and effective first-line monotherapy for advanced prostate cancer.
- Its direct mechanism prevents testosterone surge, mitigating clinical flare risk.
- Degarelix offers advantages in disease control and patient management over GnRH agonists.
